Director: Hermitage Museum Hosts over 4.5 Million Tourists Annually

The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
TT

Director: Hermitage Museum Hosts over 4.5 Million Tourists Annually

The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP
The State Hermitage Museum is seen illuminated in red for the centenary of the Bolshevik revolution in Saint Petersburg on October 25, 2017. AFP

More than 4.5 million people visit the Hermitage Museum a year, confirmed the director of the museum and the Russian Orientalist Mikhail Piotrovsky during an interview with Tass agency.

He said that this huge turnout is a "big and serious problem" that faces most of the world's major museums, including Hermitage, which accommodates thousands of visitors.

Piotrovsky said that the museum's main building can host up to 7,111 visitors, and stressed the importance of maintaining safety and security procedures during the reception of ministers.

"The ability of the Hermitage to contain this number of visitors does not mean that it can welcome them at once. Instead, we must allow the entry of the number of visitors whose exit from the museum we can secure in 10 minutes, in case a fire breaks out."

The Hermitage director said that during an international conference in the Vatican, directors of international museums discussed the protection of cities and museums from tourist flows, pointing out that "the Hermitage tackled this problem 40 years ago, when the number of visitors, was like now, about 4.5 million per year."

Piotrovsky explained that such numbers require the protection of cultural facilities without affecting the work and reception of visitors. He also saw that "the problem is twofold: the first is how to protect historic buildings, and the second is how to make museums available to anyone who wants to visit," highlighting that the museums' accommodation ability is limited and that "visitors have to recognize that the museum is like the theater."

To address this problem, museum directors participating in the Vatican International Conference formulated a set of recommendations for museum managements, including practical suggestions such as designing virtual versions featuring all museum exhibits to allow people to see them before visiting the museum.

According to the Hermitage director, the conference participants are working on developing joint international evaluation standards. The Russian orientalist said there is only one rating mechanism for museums dubbed the "Notre Dame rating" and that "the Hermitage is the fourth on Notre Dame's list."

He confirmed that his museum is currently cooperating with the Erasmus University Rotterdam to set global standards to be adopted by experts in the museums rating worldwide. He explained that based on the scientific standards of those lists, the St. Petersburg's Hermitage is always among the top ten museums in the world.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”